This is a distressed financing at the market price with massive warrant overhang. The company has only ~3 months of cash runway and faces Nasdaq delisting risk. Monitor for the BLA resubmission in June 2026 and any partnership announcements that could extend the runway. The concurrent warrant amendment at $0.5855 effectively resets the exercise price for 15.5M shares, creating additional overhang at the current price.
Price Chart
Executive Summary
Outlook Therapeutics is issuing 8,539,709 shares of common stock at $0.5855 per share to a single accredited investor, raising approximately $4.9 million in net proceeds. Concurrently, the company is amending outstanding warrants for 15,488,570 shares, reducing their exercise price from $1.78 to $0.5855 per share. The company has substantial doubt about its ability to continue as a going concern, with cash and equivalents of $7.7 million as of March 31, 2026, and expects combined funds to only sustain operations into September 2026.
Key Facts
- Offering 8,539,709 shares at $0.5855/share for ~$4.9M net proceeds
- Amending 15,488,570 warrants from $1.78 to $0.5855 exercise price
- Cash and equivalents of $7.7M as of March 31, 2026
- Combined funds with April 2026 offering ($4.5M) expected to fund operations only into September 2026
- Substantial doubt about going concern, not alleviated by this offering
- Net tangible book deficit of $0.28/share; after offering, $0.08/share deficit
- Purchaser experiences immediate dilution of $0.67/share
- Nasdaq bid price deficiency notice received February 18, 2026; compliance deadline August 17, 2026
- Outstanding warrants for 71,366,978 shares at weighted avg $1.65
- Up to $100M ATM equity program with H.C. Wainwright remains available
Financial Impact
~$4.9M net proceeds from offering; cash runway only into September 2026; immediate dilution of $0.67/share for new investors
Risk Factors
- Cash runway only into September 2026; substantial doubt about going concern
- Nasdaq delisting risk if bid price does not exceed $1.00 by August 17, 2026
- Massive dilution from 71.4M outstanding warrants and $100M ATM facility
- Third CRL from FDA for ONS-5010/LYTENAVA; BLA resubmission expected June 2026 but no guarantee of approval
- Pending securities class action and shareholder derivative lawsuits
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-067917 |
| Document: 0001104659-26-067917-index-headers.html | 0001104659-26-067917 |
| Document: 0001104659-26-067917-index.html | 0001104659-26-067917 |
| Document: 0001104659-26-067917.txt | 0001104659-26-067917 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5930 (+21.60%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5930 (+21.60%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5930 (+21.60%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5930 (−21.60%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5930 (+33.28%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5930 (+33.28%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5930 (−44.32%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5930 (−57.79%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5930 (−57.79%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5930 (−55.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access